BioSpace News Archive

AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease (PD), and mood disorders.

Modernizing the 150-year-old microscope-based practice with digital innovation

The global artificial intelligence (AI) in life sciences market size was estimated at USD 1,560 million in 2022 and is projected to soar USD 9,800 million in 2032, with a double digit CAGR of 20.21% from 2023 to 2032.

Syntec Optics today announced it will be presenting at the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the New York Athletic Club in New York City.

NovaBay Pharmaceuticals, Inc. announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes.

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that the first patients in the U.S. have been dosed as part of the ongoing Phase 1b study of CB307, Crescendo’s lead programme in PSMA+ metastatic castration-resistant prostate cancer (mCRPC).

First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the company will participate in BIO Partnering @JPM being held January 8-12, 2024 in San Francisco.

Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, announced that its senior management team is en route to Vietnam to prepare for the spring rearing season.

Rhythm Pharmaceuticals, Inc. hosted an R&D event for investors and analysts, “Rhythm Update on MC4R Pathway Programs.”

NSite Medical, a leader in scoliosis care and treatment, is excited to announce the FDA clearance of its innovative AI-based Scoliosis Assessment Application.